Análisis de la acción Exact Sciences Corp (EXAS)EXASExact Sciences Corp

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Exact Sciences Corp is not a strong buy at the moment for a beginner investor seeking long-term growth. While the company has positive catalysts such as its acquisition by Abbott and its partnership with Walgreens, the financial performance shows significant declines in net income and EPS. Additionally, hedge funds are selling, and there is no strong technical or proprietary trading signal to suggest an immediate entry point. The stock is better suited for monitoring rather than immediate investment.

13 analysts cover EXAS: 8 rate it Buy, 5 Hold and 0 Sell. The average price target is 100.20.